StreetAlpha
13F holdings · Q3 2026

Patient Square Capital

Menlo Park, CA · files as Patient Square Capital LP
Know the moment Patient Square Capital filesYou follow Patient Square Capital An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 10, 2026Next filing due Feb 15, 2027CIK 1819257

Patient Square Capital reported 23 stocks worth $627M in its 13F filing for Q3 2026, filed Nov 10, 2026. Its largest holdings are ROIV (45.0%), RVMD (6.4%) and UTHR (5.4%). Compared with Q2 2026, the fund opened new positions in ZLAB, DFTX and CMPS, added to UTHR, ARGX and PHVS, trimmed ROIV, RVMD and MIRM and sold out of XENE, DNTH and EYPT.

Latest filing: what Patient Square Capital did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
6 new8 added8 trimmed6 sold outBought about $101M · sold about $115M
New 6
See all 6 →
Added 8
See all 8 →
Trimmed 8
  • ONC−$20.7M−63%
  • RVMD−$16.4M−29%
  • ROIV−$11.3M−4%
  • BNTX−$2.9M−22%
  • IVA−$2.8M−38%
See all 8 →
Sold out 6
See all 6 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$627M−2.9% vs last quarter
Stocks held236 new · 6 sold out
Top 5 weight65.2%very concentrated
Turnover34%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
ROIV
Roivant Sciences Ltd
$282M45.0%7.7M−310K (−4%)8 of 8
2
RVMD
Revolution Medicines Inc
$40.2M6.4%196K−80K (−29%)2 of 8
3
UTHR
United Therapeutics Corp Del
$34M5.4%63K+26K (+69%)2 of 8
4
ARGX
Argenx SE
$26.8M4.3%28K+5,000 (+22%)6 of 8
5
PHVS
Pharvaris N V
$25.7M4.1%809K+137K (+20%)8 of 8
6
ABVX
Abivax SA
$24.1M3.8%243K+37K (+18%)5 of 8
7
BLTE
Belite Bio Inc
$22.4M3.6%132K+22K (+20%)3 of 8
8
MIRM
Mirum Pharmaceuticals Inc
$20M3.2%234K−27K (−10%)8 of 8
9
ZLAB
Zai Lab Ltd
$15.6M2.5%592KNew position1 of 8
10
DFTX
Definium Therapeutics Inc
$14.7M2.3%385KNew position2 of 8
🔒 13 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
XENE
Xenon Pharmaceuticals Inc
$13.3M220K
DNTH
Dianthus Therapeutics Inc
$10.5M108K
EYPT
Eyepoint Pharmaceuticals Inc
$10.3M720K
ARQT
Arcutis Biotherapeutics Inc
$9.7M370K
CCCC
C4 Therapeutics Inc
$7.5M1.6M

🔒 Free account: see all 6.

Reported value

last 8 quarters
$267MQ4 '24
$242MQ1 '25
$277MQ2 '25
$374MQ3 '25
$467MQ4 '25
$564MQ1 '26
$646MQ2 '26
$627MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 10, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Patient Square Capital 13F FAQ

What does Patient Square Capital own?

Patient Square Capital reported 23 stocks worth $627M in its 13F filing for Q3 2026, filed Nov 10, 2026. Its largest holdings are ROIV (45.0%), RVMD (6.4%) and UTHR (5.4%). The table above lists every position in the filing (the top 10 without an account).

What did Patient Square Capital buy and sell in Q3 2026?

Compared with Q2 2026: 6 new positions, 8 added to, 8 trimmed and 6 sold out. New positions include ZLAB, DFTX and CMPS. It sold all of XENE, DNTH and EYPT.

When will Patient Square Capital file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Patient Square Capital's portfolio worth?

The Q3 2026 filing reports $627M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.